Stay ahead in oncology diagnostics with this detailed course on the FDA’s proposed rule to reclassify nucleic acid-based test systems used with approved oncology therapeutic products. Learn about the transition from class III to class II, the regulatory background, device requirements, rationale for change, and the special controls FDA proposes to ensure safety and effectiveness. Gain insight into risks, benefits, and the significant impact on patient access, innovation, and compliance. Equip yourself with knowledge to respond proactively to regulatory changes and participate in the public comment process.
In this course you will learn the following:
* Explain the purpose and intent of the FDA’s proposed reclassification.
* Describe the regulatory framework for medical device classification.
* Identify the types of devices affected by the proposed rule.
* Summarize the rationale and data supporting the proposed reclassification.
* Recognize the risks to health and the proposed special controls to mitigate them.
* Understand the process and importance of public participation in the rulemaking.
* Acknowledge that the rule is not final and may change based on public input.
